VolitionRX Stock Price

0.11 (4.64%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 22,974
Bid Price
Ask Price
News -
Day High 2.4719


52 Week Range


Day Low 2.37
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
VolitionRX Limited VNRX AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.11 4.64% 2.48 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.42 2.37 2.4719 2.48 2.37
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
184 22,974 $ 2.41 $ 55,343 - 2.08 - 4.1401
Last Trade Time Type Quantity Stock Price Currency
20:00:00 808 $ 2.48 USD


Draw Mode:

VolitionRX Limited Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 133.54M 53.85M 35.69M $ 90.04k $ - -0.50 -4.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 9.60%

more financials information »

VolitionRX News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VNRX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.532.5412.262.3847,938-0.05-1.98%
1 Month2.842.942.082.4775,901-0.36-12.68%
3 Months2.643.302.082.6976,076-0.16-6.06%
6 Months3.203.572.082.8995,760-0.72-22.5%
1 Year3.654.14012.083.16120,399-1.17-32.05%
3 Years3.277.692.083.85214,852-0.79-24.16%
5 Years3.537.691.443.61162,343-1.05-29.75%

VolitionRX Description

VolitionRX Ltd is a US-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.